Pentostatin for the treatment of indolent lymphoproliferative disorders

Seminars in Hematology

Volumn 43, Issue SUPPL. 2, 2006, Pages

  Ho, Anthony D ^a   Hensel, Manfred ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ALKYLATING AGENT; ALPHA INTERFERON; ANTIBODY; ANTIINFECTIVE AGENT; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; FLUDARABINE PHOSPHATE; MITOXANTRONE; PENTOSTATIN; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CYTOPENIA; CYTOTOXICITY; DRUG ACTIVITY; DRUG INHIBITION; FEBRILE NEUTROPENIA; FEVER; HAIRY CELL LEUKEMIA; HEMATOPOIETIC CELL; HEMOLYSIS; HUMAN; IMMUNE DEFICIENCY; INFECTION; LEUKEMIA CELL; LUNG TOXICITY; LYMPHATIC LEUKEMIA; LYMPHATIC SYSTEM; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE MYELOMA; MYELOID PROGENITOR CELL; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; PURINE METABOLISM; REVIEW; SKIN MANIFESTATION; SPLENECTOMY; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; WALDENSTROEM MACROGLOBULINEMIA;

EID: 33645016311     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2005.12.005     Document Type: Article

References (92)

1. A.D. Ho, W. Knauf, K. Ganeshaguru, W. Hunstein, A.V. Hoffbrand Purine degradative enzymes in circulating malignant cells of patients with chronic B cell neoplasia Hematol Oncol 5 1987 9 17
2. E.R. Giblett, J.E. Anderson, F. Cohen, B. Pollara, H.J. Meuwissen Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity Lancet 2 1972 1067 1069
3. E.R. Giblett, A.J. Ammann, D.W. Wara, R. Sandman, L.K. Diamond Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity Lancet 1 1975 1010 1013
4. W.D. Biggar, E.R. Giblett, R.L. Ozere, B.D. Grover A new form of nucleoside phosphorylase deficiency in two brothers with defective T-cell function J Pediatr 92 1978 354 357
5. R. Barton, F. Martiniuk, R. Hirschhorn, I. Goldschneider The distribution of adenosine deaminase among lymphocyte populations in the rat J Immunol 122 1979 216 220
6. B.E. Chechik, W.P. Schrader, J. Minowada An immunomorphologic study of adenosine deaminase distribution in human thymus tissue, normal lymphocytes, and hematopoietic cell lines J Immunol 126 1981 1003 1007
7. R. Tung, R. Silber, F. Quagliata, M. Conklyn, J. Gottesman, R. Hirschhorn Adenosine deaminase activity in chronic lymphocytic leukemia. Relationship to B- and T-cell subpopulations J Clin Invest 57 1976 756 761
8. K. Ganeshaguru, N. Lee, P. Llewellin, H.G. Prentice, A.V. Hoffbrand, D. Catovsky Adenosine deaminase concentrations in leukaemia and lymphoma Relation to cell phenotypes Leuk Res 5 1981 215 222
9. A.D. Ho, K. Ganeshaguru Enzymes of purine metabolism in lymphoid neoplasms, clinical relevance for treatment with enzyme inhibitors Klin Wochenschr 66 1988 467 474
10. A. Cohen, R. Hirschhorn, S.D. Horowitz, A. Rubinstein, S.H. Polmar, R. Hong Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency Proc Natl Acad Sci U S A 75 1978 472 476
11. M.S. Hershfield, N.M. Kredich Resistance of an adenosine kinase-deficient human lymphoblastoid cell line to effects of deoxyadenosine on growth, S-adenosylhomocysteine hydrolase inactivation, and dATP accumulation Proc Natl Acad Sci U S A 77 1980 4292 4296
12. M.S. Hershfield, N.M. Kredich, C.A. Koller, B.S. Mitchell, J. Kurtzberg, T.R. Kinney S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2′-deoxycoformycin alone and in combination with 9-beta-D- arabinofuranosyladenine Cancer Res 43 1983 3451 3458
13. A.D. Ho, K. Ganeshaguru, W.U. Knauf, G. Dietz, I. Trede, W. Hunstein Clinical response to deoxycoformycin in chronic lymphoid neoplasms and biochemical changes in circulating malignant cells in vivo Blood 72 1988 1884 1890
14. K. Ganeshaguru, A.D. Ho, A. Piga, D. Catovsky, A.V. Hoffbrand Biochemical mechanisms of deoxycoformycin toxicity in chronic leukemias Leuk Res 11 1987 941 945
15. E.W. Gelfand, J.J. Lee, H.M. Dosch Selective toxicity of purine deoxynucleosides for human lymphocyte growth and function Proc Natl Acad Sci U S A 76 1979 1998 2002
16. P.W.K. Woo, H.W. Dion, S.M. Lange, L.F. Dahl, L.J. Durham A novel adenosine and araA deaminase inhibitor, (R)-3-(2-deoxy-β-D-Erythro-pento- furanosyl)-3,6,7,8-tetra-hydroimidazo (4,5-d) (1,3) diazepin-8-ol J Heterocyclic Chem 11 1974 641 643
17. R.P. Agarwal, T. Spector, R.E.J. Parks Inhibition of adenosine deaminase by various inhibitors Biochem Pharmacol 26 1977 359 367
18. D.G. Poplack, S.E. Sallan, G. Rivera, J. Holcenberg, S.B. Murphy, J. Blatt Phase I study of 2′-deoxycoformycin in acute lymphoblastic leukemia Cancer Res 41 1981 3343 3346
19. H.G. Prentice, J.F. Smyth, K. Ganeshaguru, B. Wonke, K.F. Bradstock, G. Janossy Remission induction with adenosine-deaminase inhibitor 2′-deoxycoformycin in Thy-lymphoblastic leukaemia Lancet 2 1980 170 172
20. H.G. Prentice, N.H. Russell, N. Lee, K. Ganeshaguru, H. Blacklock, A. Piga Therapeutic selectivity of and predication of response to 2′-deoxycoformycin in acute leukaemia Lancet 2 1981 1250 1254
21. J.F. Smyth, R.M. Paine, A.L. Jackman, K.R. Harrap, M.M. Chassin, R.H. Adamson The clinical pharmacology of the adenosine deaminase inhibitor 2′-deoxycoformycin Cancer Chemother Pharmacol 5 1980 93 101
22. M.R. Grever, M.F. Siaw, W.F. Jacob, J.A. Neidhart, J.S. Miser, M.S. Coleman The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy Blood 57 1981 406 417
23. M.R. Grever, J.M. Leiby, E.H. Kraut, H.E. Wilson, J.A. Neidhart, R.L. Wall Low-dose deoxycoformycin in lymphoid malignancy J Clin Oncol 3 1985 1196 1201
24. A.S. Spiers, J.C. Ruckdeschel, J. Horton Effectiveness of pentostatin (2′-deoxycoformycin) in refractory lymphoid neoplasms Scand J Haematol 32 1984 130 134
25. A.D. Ho, J. Thaler, P. Stryckmans, B. Coiffier, M. Luciani, P. Sonneveld Pentostatin in refractory chronic lymphocytic leukemia A phase II trial of the European Organization for Research and Treatment of Cancer J Natl Cancer Inst 82 1990 1416 1420
26. S. Seto, C.J. Carrera, M. Kubota, D.B. Wasson, D.A. Carson Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes J Clin Invest 75 1985 377 383
27. M.F. Siaw, M.S. Coleman In vitro metabolism of deoxycoformycin in human T lymphoblastoid cells. Phosphorylation of deoxycoformycin and incorporation into cellular DNA J Biol Chem 259 1984 9426 9433
28. A. Polliack Hairy cell leukemia Biology, clinical diagnosis, unusual manifestations and associated disorders Rev Clin Exp Hematol 6 2002 366 388
29. J.R. Quesada, J. Reuben, J.T. Manning, E.M. Hersh, J.U. Gutterman Alpha interferon for induction of remission in hairy-cell leukemia N Engl J Med 310 1984 15 18
30. M.J. Ratain, H.M. Golomb, J.W. Vardiman, E.E. Vokes, R.H. Jacobs, K. Daly Treatment of hairy cell leukemia with recombinant alpha 2 interferon Blood 65 1985 644 648
31. H.M. Golomb, A. Jacobs, A. Fefer, H. Ozer, J. Thompson, C. Portlock Alpha-2 interferon therapy of hairy-cell leukemia A multicenter study of 64 patients J Clin Oncol 4 1986 900 905
32. A.D. Ho, J. Thaler, F. Mandelli, F. Lauria, R. Zittoun, R. Willemze The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha J Clin Oncol 7 1989 1533 1538
33. E.H. Kraut, B.A. Bouroncle, M.R. Grever Pentostatin in the treatment of advanced hairy cell leukemia J Clin Oncol 7 1989 168 172
34. P.A. Cassileth, B. Cheuvart, A.S. Spiers, D.P. Harrington, F.J. Cummings, R.S. Neiman Pentostatin induces durable remissions in hairy cell leukemia J Clin Oncol 9 1991 243 246
35. J.B. Johnston, E. Eisenhauer, W.E. Corbett, J.G. Scott, S.D. Zaentz Efficacy of 2′-deoxycoformycin in hairy-cell leukemia A study of the National Cancer Institute of Canada Clinical Trials Group J Natl Cancer Inst 80 1988 765 769
36. H.M. Golomb, R. Dodge, R. Mick, D. Budman, R. Hutchison, S.J. Horning Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon A report of CALGB study 8515 Leukemia 8 1994 2037 2040
37. M. Grever, K. Kopecky, M.K. Foucar, D. Head, J.M. Bennett, R.E. Hutchison Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia An intergroup study J Clin Oncol 13 1995 974 982
38. I.W. Flinn, K.J. Kopecky, M.K. Foucar, D. Head, J.M. Bennett, R. Hutchison Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin Blood 96 2000 2981 2986
39. G.R. Goodman, C. Burian, J.A. Koziol, A. Saven Extended follow-up of patients with hairy cell leukemia after treatment with cladribine J Clin Oncol 21 2003 891 896
40. A. Saven, C. Burian, J.A. Koziol, L.D. Piro Long-term follow-up of patients with hairy cell leukemia after cladribine treatment Blood 92 1998 1918 1926
41. I.W. Flinn, M.R. Grever Chronic lymphocytic leukemia Cancer Treat Rev 22 1996 1 13
42. K.R. Rai, B.L. Peterson, F.R. Appelbaum, J. Kolitz, L. Elias, L. Shepherd Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia N Engl J Med 343 2000 1750 1757
43. R.O. Dillman, R. Mick, O.R. McIntyre Pentostatin in chronic lymphocytic leukemia A phase II trial of Cancer and Leukemia Group B J Clin Oncol 7 1989 433 438
44. S.A. Johnson, D. Catovsky, J.A. Child, A.C. Newland, D.W. Milligan, R. Janmohamed Phase I/II evaluation of pentostatin (2′-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia Invest New Drugs 16 1998 155 160
45. C.E. Dearden, E. Matutes, D. Catovsky Clinical overview of pentostatin (Nipent) use in lymphoid malignancies Semin Oncol 27 2000 22 26
46. M.A. Weiss, P.G. Maslak, J.G. Jurcic, D.A. Scheinberg, T.B. Aliff, N. Lamanna Pentostatin and cyclophosphamide An effective new regimen in previously treated patients with chronic lymphocytic leukemia J Clin Oncol 21 2003 1278 1284
47. M.M. Oken, S. Lee, N.E. Kay, W. Knospe, P.A. Cassileth Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia A phase I/II study by the Eastern Cooperative Oncology Group study E1488 Leuk Lymphoma 45 2004 79 84
48. N. Di Bella, C. Reynolds, D. Faragher, J. Muscato, K.A. Boehm, L. Asmar An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, stage III or IV, low-grade non-Hodgkin lymphoma Cancer 103 2005 978 984
49. M.A. Dimopoulos, R.A. Kyle, A. Anagnostopoulos, S.P. Treon Diagnosis and management of Waldenstrom's macroglobulinemia J Clin Oncol 23 2005 1564 1577
50. J. Waldenstrom Incipient myelomatosis of "essential" hyperglobulinemia with fibrinogenopenia A new syndrome Acta Med Scand 117 1944 216 222
51. P. Lin, L.J. Medeiros Lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia An evolving concept Adv Anat Pathol 12 2005 246 255
52. M.A. Gertz Waldenstrom macroglobulinemia A review of therapy Am J Hematol 79 2005 147 157
53. D.M. Weber, M.A. Dimopoulos, K. Delasalle, K. Rankin, M. Gavino, R. Alexanian 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia Semin Oncol 30 2003 243 247
54. H.M. Kantarjian, R. Alexanian, C.A. Koller, R. Kurzrock, M.J. Keating Fludarabine therapy in macroglobulinemic lymphoma Blood 75 1990 1928 1931
55. M.V. Dhodapkar, J.L. Jacobson, M.A. Gertz, S.E. Rivkin, G.D. Roodman, J.M. Tuscano Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia Results of United States intergroup trial (Southwest Oncology Group S9003) Blood 98 2001 41 48
56. V. Leblond, V. Levy, F. Maloisel, B. Cazin, J.P. Fermand, J.L. Harousseau Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease Blood 98 2001 2640 2644
57. K. Fenchel, P. Wijermans, P.S. Mitrou, D. Hoelzer, L. Bergmann Fludarabine is an effective agent in immunocytic lymphoma Onkologie 17 1994 508 513
58. M. Bjorkholm, F. Celsing, G. Runarsson, J. Waldenstrom Successful intravenous immunoglobulin therapy for severe and persistent astrovirus gastroenteritis after fludarabine treatment in a patient with Waldenstrom's macroglobulinemia Int J Hematol 62 1995 117 120
59. P. Costa, R. Luzzati, A. Nicolato, G. Perboni, A. Scalzini, L. Lazzarini Cryptococcal meningitis and intracranial tuberculoma in a patient with Waldenstrom's macroglobulinemia treated with fludarabine Leuk Lymphoma 28 1998 617 620
60. M.A. Dimopoulos, S. O'Brien, H. Kantarjian, E.E. Estey, M.J. Keating, R. Alexanian Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues Leuk Lymphoma 11 suppl 2 1993 105 108
61. E.S. Liu, C. Burian, W.E. Miller, A. Saven Bolus administration of cladribine in the treatment of Waldenstrom macroglobulinaemia Br J Haematol 103 1998 690 695
62. A. Hellmann, K. Lewandowski, J.M. Zaucha, M. Bieniaszewska, K. Halaburda, T. Robak Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenstrom's macroglobulinemia Eur J Haematol 63 1999 35 41
63. D.C. Betticher, S.F. Hsu Schmitz, D. Ratschiller, A. von Rohr, T. Egger, P. Pugin Swiss Group for Clinical Cancer Research (SAKK) Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenstrom's macroglobulinaemia Br J Haematol 99 1997 358 363
64. H.M. Bryson, E.M. Sorkin Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies Drugs 46 1993 872 894
65. E. Van Den Neste, I. Louviaux, J.L. Michaux, A. Delannoy, L. Michaux, A. Hagemeijer Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2′-deoxyadenosine Br J Haematol 105 1999 268 270
66. E. Van Den Neste, A. Delannoy, W. Feremans, A. Ferrant, L. Michaux Second primary tumors and immune phenomena after fludarabine or 2-chloro-2′- deoxyadenosine treatment Leuk Lymphoma 40 2001 541 550
67. S.A. Tetreault, A. Saven Delayed onset of autoimmune hemolytic anemia complicating cladribine therapy for Waldenstrom macroglobulinemia Leuk Lymphoma 37 2000 125 130
68. D.M. Weber, M. Gavino, Y. Huh Phenotypic and clinical evidence supports rituximab for Waldenstrom's macroglobulinemia Blood 94 1999 125a (abstr 551)
69. J.M. Foran, A.Z. Rohatiner, D. Cunningham, R.A. Popescu, P. Solal-Celigny, M. Ghielmini European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma J Clin Oncol 18 2000 317 324
70. S.P. Treon, T.B. Agus, B. Link, G. Rodrigues, A. Molina, M.Q. Lacy CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia J Immunother 24 2001 272 279
71. M.A. Dimopoulos, C. Zervas, A. Zomas, C. Kiamouris, N.A. Viniou, V. Grigoraki Treatment of Waldenstrom's macroglobulinemia with rituximab J Clin Oncol 20 2002 2327 2333
72. S.P. Treon, C. Emmanouilides, E. Kimby, A. Kelliher, F. Preffer, A.R. Branagan Extended rituximab therapy in Waldenstrom's macroglobulinemia Ann Oncol 16 2005 132 138
73. M.A. Gertz, M. Rue, E. Blood, L.S. Kaminer, D.H. Vesole, P.R. Greipp Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM) An Eastern Cooperative Oncology Group Study (E3A98) Leuk Lymphoma 45 2004 2047 2055
74. S.P. Treon, A.R. Branagan, P. Wasi Combination therapy with rituximab and fludarabine in Waldenstrom's macroglobulinemia 2004 57 3rd International Workshop on Waldenstrom's Macroglobulinemia. Paris, France, October 7-10
75. S. Riddell, J.B. Johnston, H.L. Rayner, L.G. Israels Response of Waldenstrom's macroglobulinemia to pentostatin (2′-deoxycoformycin) Cancer Treat Rep 70 1986 546 548
76. N. Lamanna, M. Kalaycio, P.G. Maslak, J.G. Jurcic, D.A. Scheinberg, A.N. Gencarelli Pentostatin and cyclophosphamide with or without rituximab has significant activity in patients with previously treated chronic lymphocytic leukemia and other low grade lymphoid neoplasms Blood 104 2004 950a (abstr)
77. M. Hensel, F. Krasniqi, M. Villabos, M. Kornacker, A.D. Ho Pentostatin and cylcophosphamide followed by maintenance therapy with rituximab for previously treated patients with B-cell chronic lymphocytic leukaemia, and Walendstroem's macroglobulinemia Blood 102 2003 404a (abstr)
78. R. Desikan, M. Dhodapkar, D. Siegel, A. Fassas, J. Singh, S. Singhal High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom's macroglobulinaemia Br J Haematol 105 1999 993 996
79. A. Anagnostopoulos, M.A. Dimopoulos, A. Aleman, D. Weber, R. Alexanian, R. Champlin High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia Bone Marrow Transplant 27 2001 1027 1029
80. O. Tournilhac, V. Leblond, R. Tabrizi, R. Gressin, D. Senecal, N. Milpied Transplantation in Waldenstrom's macroglobulinemia - The French experience Semin Oncol 30 2003 291 296
81. P. Dreger, S. Stilgenbauer, B. Seyfarth Autologous and allogeneic stem cell transplantation for treatment of Waldenstrom's macroglobulinemia 2004 70 3rd International Workshop on Waldenstrom's Macroglobulinemia. Paris, France, October 7-10
82. A. Fassas, M. Dhodapkar, J. McCoy Management of Waldenstrom's macroglobulinemia in the pre-rituximab era Update on US Intergroup Trial S9003 and the Arkansas autotransplant experience 2004 59 3rd International Workshop on Waldenstrom's Macroglobulinemia. Paris, France, October 7-10
83. E. Leo, L. Scheuer, I.G. Schmidt-Wolf, M. Kerowgan, C. Schmitt, A. Leo Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma Eur J Haematol 73 2004 251 257
84. M.J. Keating, H. Kantarjian, M. Talpaz, J. Redman, C. Koller, B. Barlogie Fludarabine A new agent with major activity against chronic lymphocytic leukemia Blood 74 1989 19 25
85. M. Montillo, A. Tedeschi, S. O'Brien, F. Di Raimondo, S. Lerner, A. Ferrajoli Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia Cancer 97 2003 114 120
86. S.M. O'Brien, H.M. Kantarjian, J. Cortes, M. Beran, C.A. Koller, F.J. Giles Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia J Clin Oncol 19 2001 1414 1420
87. R. Drapkin, N.J. Di Bella, D.C. Faragher, E. Harden, C. Matei, W. Hyman Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin's lymphoma An effective and minimally toxic regimen Clin Lymphoma 4 2003 169 175
88. M.S. Czuczman, A. Koryzna, A. Mohr, C. Stewart, K. Donohue, L. Blumenson Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma J Clin Oncol 23 2005 694 704
89. W. Wierda, S. O'Brien, S. Wen, S. Faderl, G. Garcia-Manero, D. Thomas Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia J Clin Oncol 23 2005 4070 4078
90. M.J. Keating, S. O'Brien, M. Albitar, S. Lerner, W. Plunkett, F. Giles Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia J Clin Oncol 23 2005 4079 4088
91. T. Robak, J.Z. Blonski, J. Gora-Tybor, M. Kasznicki, J. Dwilewicz-Trojaczek, A. Tomaszewska Cladribine alone or in combination with cyclophosphamide or cyclophosphamide and mitoxantrone as first line treatment in chronic lymphocytic leukemia An early report of prospective randomized study Blood 104 2004 337a (abstr)
92. M. Hensel, M. Villalobos, M. Kornacker, F. Krasniqi, A.D. Ho Pentostatin/cyclophosphamide with or without rituximab An effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma Clin Lymphoma Myeloma 6 2005 131 135